Individuals who have suffered from TDF medication side effects such as osteopenia, osteoporosis, and bone injuries may be entitled to legal restitution. Extended exposure to tenofovir disoproxil fumarate (the active ingredient in TDF drugs) is associated with accelerated bone mineral loss, putting patients at increased risk for bone injuries including osteopenia, osteoporosis, and bone fractures. Truvada and other HIV drugs containing tenofovir disoproxil fumarate are among the most commonly prescribed antiretrovirals, however manufacturer Gilead Sciences placed trusting patients at serious risk by withholding a safer alternative design of tenofovir.
HIV Litigation for Bone Loss After Exposure to TDF Drugs
Gilead, which has long dominated the HIV drug market, is facing a growing number of lawsuits filed by patients who developed TDF-related bone loss when a safer and more effective alternative was available.
HIV Litigation Attorneys™ provide strategic, client-focused representation to those who experienced bone density loss, osteopenia, osteoporosis, and other injuries from Truvada and other TDF drugs manufactured by Gilead. Our talented legal team is taking TDF bone loss claims on a contingency fee basis, meaning there are no costs unless we procure monetary damages on your behalf.
Truvada and Osteopenia
TDF HIV drugs, such as Truvada, Complera, Atripla, Viread and Stribild, have been a distinctive component of active antiretroviral therapy in patients who test positive for HIV. For more than a decade, Gilead’s TDF drugs have been the front-line HIV treatment, reaping billions in yearly sales for the pharmaceutical giant.
Gilead is accused of failing to warn about TDF drugs and bone density loss, leaving unsuspecting patients at risk for preventable harm. The FDA admonished the drug maker on several occasions for downplaying the risk of osteopenia and fractures in its TDF marketing, while making misleading claims about the effectiveness of the medication.
While hormone fluctuations, age, genetics, race, and HIV status are among known risk factors for mild bone mineral loss (a condition known as osteopenia), the action of TDF within the body may cause or accelerate the condition. Bones that lose mineral density become brittle and more susceptible to fractures.
HIV litigation against Gilead argues that Gilead’s labels were insufficient to warn of these dangers and Gilead did not encourage doctors to warn their patients about osteopenia risks from TDF drugs.
Osteoporosis Symptoms and Diagnosis
Osteopenia may be a precursor to osteoporosis (abnormally porous bone), a disease for which there is no cure. Osteoporosis is often difficult to detect because it lacks noticeable symptoms. Osteoporosis-related fractures of the wrist, hips, and spine due to a significant decline in bone density are typically the first sign of the disease.
Some bone fractures escape initial detection. For example, fractures of the spinal vertebra usually trigger severe pain that radiates to the sides of the body. These fractures are often slow to heal and can result in a serious reduction in quality of life for the patient.
Decreased bone strength is a normal part of the aging process, but this progression may be accelerated in patients taking HIV medications containing tenofovir disoproxil fumarate (TDF). We believe that osteopenia and bone fractures are a risk to anyone taking Truvada or other TDF drugs.
Unfortunately, Truvada-related bone loss has been reported not only in HIV positive patients on the medication, but also those taking the antiretroviral drug for prophylactic purposes. In a recently filed Truvada lawsuit, the plaintiff alleges that he suffered compound fractures in his forearm after a minor fall as a direct result of bone loss from the medication, which was deceptively marketed.
Patients who are currently taking or have been exposed to TDF drugs are encouraged to discuss bone mineral density testing with their health care professionals.
Litigation against Gilead Sciences contends that the company also suppressed information regarding a much safer tenofovir drug (TAF), which was purposefully withheld from the market until the TDF patent expired. Plaintiffs across the country believe that this is a clear example of corporate greed, where Gilead took unjust and unduly dangerous measures to safeguard long-term profits from its first formulation.
HIV Litigation Attorneys™ Can Help You
If you have taken a Gilead HIV drug containing TDF, and have suffered osteoporosis-related bone fractures, you may have a strong claim for compensation. Litigation can hold pharmaceutical manufacturers accountable for their actions, while recovering much-needed funds for your expenses, pain, and suffering. HIV Litigation Attorneys™ have the resources and skill to advocate on your behalf. Our lawyers have in-depth experience handling complex litigation in state and federal court. Reach out today for a free case evaluation.
Additional HIV Medication Bone Injury Resources:
- US Department of Health and Human Services, HIV and Osteoporosis https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/22/62/hiv-and-osteoporosis
- Therapeutics and Clinical Risk Management, Tenofovir-associated bone density loss https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817787/
- POV, HIV and Your Bones https://www.poz.com/basics/hiv-basics/hiv-bones
- ContagionLive, PrEP May Cause Loss in Bone Density, but Alternatives Are Available https://www.contagionlive.com/news/prep-may-cause-loss-in-bone-density-but-alternatives-are-available
- AidsMap.com, Modest bone loss seen in young men taking Truvada for pre-exposure prophylaxis http://www.aidsmap.com/Modest-bone-loss-seen-in-young-men-taking-Truvada-for-pre-exposure-prophylaxis/page/3008328/